Insulin delivery system maker for people with diabetes
Sequel Med Tech is a young diabetes-care device company built around an insulin delivery system, with job posts pointing to a new insulin pump launch and further products behind it. Hiring is almost entirely senior field sales focused on territory-level adoption, a commercialization push rather than R&D build-out, while a Salesforce, MuleSoft and Snowflake core with dbt and Airflow signals a data-driven commercial operation.
Sequel Med Tech develops insulin delivery technology for people living with diabetes. Founded in 2023 and headquartered in Manchester, New Hampshire, the privately held company employs 201–500 people. Its go-to-market relies on territory-based sales teams promoting product adoption across the United States, supported by medical information and education functions. Internal systems include Salesforce, Salesforce Marketing Cloud, NetSuite, Snowflake, and AWS.
Sequel runs Salesforce (Apex, Lightning, Marketing Cloud), MuleSoft, NetSuite, and AWS, with a data stack of Snowflake, dbt, Airbyte, Apache Airflow, Databricks, and Tableau.
Yes. Current hiring centers on senior sales roles in the United States, focused on driving insulin delivery system adoption in assigned territories, including Utah. Overall hiring velocity is slowing.
Sequel Med Tech is headquartered in Manchester, New Hampshire. It was founded in 2023 and has 201–500 employees.
Other companies in the same industry, closest in size
Sequel Med Tech's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.